title: 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.
abstract: BACKGROUND
  The aryl hydrocarbon receptor (AhR) ligand 6-Formylindolo(3,2-b)carbazole (FICZ) has received increasing attention since its identification as an endogenous AhR ligand and a photoproduct of tryptophan. FICZ and its metabolites have been detected in human fluids. We recently reported that AhR promotes retinoic acid (RA)-induced granulocytic differentiation of HL-60 myeloblastic leukemia cells by restricting the nuclear abundance of the stem cell associated transcription factor Oct4. The standard clinical management of acute promyelocytic leukemia (APL) is differentiation induction therapy using RA. But RA is not effective for other myeloid leukemias, making the mechanism of RA-induced differentiation observed in a non-APL myeloid leukemia of interest. To our knowledge, this is the first study regarding the influence of FICZ on RA-induced differentiation in any type of leukemic blasts.
  
  
  METHODS
  Using flow cytometry and Western blotting assays, we determined the effects of FICZ on RA-induced differentiation of HL-60 human leukemia cells. All experiments were performed in triplicate. The groups RA and FICZ + RA were compared using the Paired-Samples T-Test. Western blot figures present the typical blots.
  
  
  RESULTS
  We demonstrate that FICZ enhances RA-induced differentiation, assessed by the expression of the membrane differentiation marker CD11b; cell cycle arrest; and the functional differentiation marker, inducible-oxidative metabolism. FICZ causes changes in signaling events that are known to drive differentiation, and notably augments the RA-induced sustained activation of the RAF/MEK/ERK axis of the mitogen-activated protein kinase (MAPK) cascade. FICZ also augments expression of the known MAPK signaling regulatory molecules c-Cbl, VAV1, pY458 p85 PI3K, Src-family kinases (SFKs), and IRF-1, a transcription factor associated with this putative signalsome that promotes RA-induced differentiation. Moreover, FICZ in combination with RA also increases expression of AhR and even more so of both Cyp1A2 and p47phox, which are known to be transcriptionally regulated by AhR. pY1021 PDGFRβ, a marker associated with retinoic acid syndrome was also increased.
  
  
  CONCLUSIONS
  Our data suggest that FICZ modulates intracellular signaling pathways and enhances RA-induced differentiation.
authors: Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853, USA.
authors: Rodica P
authors: RP
authors: Bunaciu
authors: Andrew
authors: A
authors: Yen
mesh_terms: D002227:Carbazoles / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects* / Q000235:genetics; D004357:Drug Synergism; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D008024:Ligands; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D008954:Models, Biological; D010766:Phosphorylation / Q000187:drug effects; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D018336:Receptors, Aryl Hydrocarbon / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: C111855:6-formylindolo(3,2-b)carbazole; D002227:Carbazoles; D008024:Ligands; D018336:Receptors, Aryl Hydrocarbon; D014212:Tretinoin; D019908:Proto-Oncogene Proteins c-raf; D020928:Mitogen-Activated Protein Kinases
references: Nature. 2007 Mar 29;446(7135):562-6
references: 17392787
references: Curr Drug Metab. 2001 Jun;2(2):149-64
references: 11469723
references: Cell. 2006 Aug 25;126(4):663-76
references: 16904174
references: Zoolog Sci. 2004 May;21(5):541-51
references: 15170058
references: Arch Biochem Biophys. 2000 Jan 1;373(1):163-74
references: 10620335
references: J Biol Chem. 2009 Sep 18;284(38):25664-77
references: 19635790
references: J Proteome Res. 2008 Sep;7(9):3729-36
references: 18642942
references: Exp Cell Res. 2008 Oct 1;314(16):2999-3006
references: 18692045
references: Biochimie. 2006 Mar-Apr;88(3-4):387-97
references: 16480812
references: In Vitro Cell Dev Biol Anim. 2000 Apr;36(4):249-55
references: 10852350
references: FEBS Lett. 2008 Jul 23;582(17):2508-14
references: 18571505
references: Biol Chem. 2013 Jun;394(6):729-39
references: 23370907
references: Leuk Lymphoma. 2012 Sep;53(9):1779-84
references: 22356114
references: Cancer Res. 2007 Aug 15;67(16):7765-72
references: 17699781
references: Eur J Cell Biol. 2006 Feb;85(2):117-32
references: 16439309
references: Biochem Pharmacol. 1996 Nov 22;52(10):1599-612
references: 8937476
references: Cancer Res. 1998 Jul 15;58(14):3163-72
references: 9679985
references: Toxicol Appl Pharmacol. 2002 Jun 1;181(2):116-23
references: 12051995
references: J Biol Chem. 2002 Jun 28;277(26):23949-57
references: 11971897
references: Am J Ind Med. 2002 Dec;42(6):474-80
references: 12439870
references: Mol Cell. 2005 Jan 21;17(2):215-24
references: 15664191
references: Cancer Res. 2008 Nov 1;68(21):8761-9
references: 18974118
references: Cell. 1996 May 3;85(3):403-14
references: 8616895
references: Leuk Lymphoma. 2011 Dec;52(12):2372-9
references: 21740303
references: Cancer Res. 2011 Mar 15;71(6):2371-80
references: 21262915
references: Carcinogenesis. 2013 Jul;34(7):1620-7
references: 23455376
references: Blood. 1996 Jan 1;87(1):227-37
references: 8547646
references: Mol Pharmacol. 1992 Oct;42(4):603-12
references: 1331752
references: In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):527-32
references: 10548434
references: J Biol Chem. 1996 May 10;271(19):11557-62
references: 8626717
references: Biochem Biophys Res Commun. 1998 Dec 18;253(2):346-51
references: 9878540
references: Genes Cells. 1997 Oct;2(10):645-54
references: 9427285
references: J Biol Chem. 2008 Feb 15;283(7):4375-86
references: 18006504
references: Free Radic Biol Med. 2009 Sep 15;47(6):825-34
references: 19559082
references: Cancer Res. 2010 Jan 1;70(1):212-20
references: 19996281
references: Cell. 1998 Oct 30;95(3):379-91
references: 9814708
references: Mol Cell Biol. 1992 Oct;12(10):4666-76
references: 1328857
references: Leukemia. 2012 Jun;26(6):1180-8
references: 22182854
references: New Biol. 1991 Dec;3(12):1206-19
references: 1667479
references: Mol Endocrinol. 2010 Feb;24(2):359-69
references: 20032195
references: Am J Pathol. 1972 Mar;66(3):589-92
references: 4551297
references: Cell Commun Signal. 2012 Jul 17;10(1):21
references: 22805580
references: J Biol Chem. 2003 Aug 29;278(35):32544-51
references: 12805378
references: FEBS Lett. 2005 Jan 17;579(2):464-8
references: 15642359
references: Science. 2010 Sep 10;329(5997):1345-8
references: 20688981
references: J Nutr. 2003 Jan;133(1):277S-281S
references: 12514309
references: Arch Biochem Biophys. 2010 Sep 1;501(1):134-41
references: 20450880
references: Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20597-8
references: 21084638
references: Gene Expr. 1999;8(5-6):273-86
references: 10947077
references: Science. 2007 Dec 21;318(5858):1917-20
references: 18029452
references: J Biol Chem. 2005 Feb 25;280(8):6872-8
references: 15591313
references: Biochemistry. 1998 Feb 3;37(5):1438-46
references: 9477973